AI Article Synopsis
- A 3D clinostat creates a low gravity environment (approximately 10(-3)G), where human malignant glioma cells were cultured to study their growth and response to chemotherapy.
- Growth of glioma cell lines was significantly inhibited in this microgravity-like condition, but the cell cycle remained unaffected, indicating a slowdown in mitosis.
- The cells showed increased sensitivity to the chemotherapy drug cisplatin when grown in the 3D clinostat, suggesting its potential as a treatment for malignant gliomas and a research tool in developmental biology.
Article Abstract
A three-dimensional (3D) clinostat is a device for generating multidirectional G force, resulting in an environment with an average of 10(-3)G. We cultured human malignant glioma cell lines in a 3D-clinostat (CL group) and examined the growth properties and chemosensitivity of the cells compared to cells cultured under normal 1G conditions (C group). The growth rate was significantly inhibited in the CL group, but without cell cycle change. Mitochondrial activity was also inhibited in the CL group. Thus, inhibition of malignant glioma proliferation occurred that could be attributed to deceleration of mitosis. Chemosensitivity to cisplatin (cis-diamminedichloroplatinum(II), CDDP) in the CL group was significantly enhanced compared to the C group. This method has significant potential as a treatment of malignant gliomas and a tool for understanding developmental biology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neulet.2009.07.045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and validation of mitochondria-related LncRNA signatures as a novel prognostic model for glioma.
Anticancer Drugs
January 2025
Department of Neurosurgery, Binzhou Medical University Hospital, Binzhou.
A predictive model for long-term survival is needed, and mitochondrial dysfunction is a key feature of cancer metabolism, though its link to glioma is not well understood. The aim of this study was to identify the molecular characteristics associated with glioma prognosis and explore its potential function. We analyzed RNA-seq data from The Cancer Genome Atlas and identified differentially expressed mitochondrial long noncoding RNAs (lncRNAs) using R's 'limma' package.
View Article and Find Full Text PDFFDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
Clin Cancer Res
January 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was radiologic overall response rate (ORR), defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.
View Article and Find Full Text PDFIdentification of Key Biomarkers Associated with Glioma Hemorrhage: Evidence from Bioinformatic Analysis and Clinical Validation.
J Mol Neurosci
January 2025
Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Hemorrhagic stroke is a known complication of glioma, yet the underlying mechanisms remain poorly understood. This study aims to investigate key biomarkers of glioma-related hemorrhage to provide insights into glioma molecular therapies. Data were obtained from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases to analyze differentially expressed genes (DEGs) in glioma by contrasting glioblastoma (GBM) with low-grade gliomas (LGGs).
View Article and Find Full Text PDFAssociation between hormone therapy and glioma risk in US women: a cancer screening trial.
Menopause
January 2025
From the Department of Neurosurgery, Chongqing General Hospital, Chongqing University, Chongqing, China.
Objective: Gliomas are the most common primary brain tumors in adults, and the role of hormone therapy (HT) in their development remains controversial. This study with a cohort design aimed to investigate the association between HT use and glioma risk using the data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Methods: We analyzed data from 75,335 women, aged 50-78, who were enrolled between 1993 and 2001.
Identifying cancer prognosis genes through causal learning.
Brief Bioinform
November 2024
School of Artificial Intelligence, Jilin University, 3003 Qianjin Street, 130012 Changchun, China.
Accurate identification of causal genes for cancer prognosis is critical for estimating disease progression and guiding treatment interventions. In this study, we propose CPCG (Cancer Prognosis's Causal Gene), a two-stage framework identifying gene sets causally associated with patient prognosis across diverse cancer types using transcriptomic data. Initially, an ensemble approach models gene expression's impact on survival with parametric and semiparametric hazard models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!